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MDL 17,043: Short- and Long-Term Cardiopulmonary and Clinical
Effects in Patients With Heart Failure
STANLEY A. RUBIN, MD, FACC, LINDA TABAK, RN
Los Angeles. California
MOL 17,043, an inotropic and vasodilator drug, is be-
lieved to have beneficial effects in patients with heart
failure. Its short- and long-term hemodynamic and car-
diopulmonary effects were studied in 10 patients with
New York Heart Association functional class III heart
failure who were maintained on digitalis and diuretic
drugs. Hemodynamics at baseline study and after 24
hours of oral therapy (four doses of 6 mg/kg) showed
increased cardiac output (3.9 ± 0.7 to 6.1 ± 1.1 li-
ters/min, p < 0.05), increased stroke volume (42 ± 12
to 60 ± 15 ml, p < 0.05), decreased systemic vascular
resistance (1,564 ± 326 to 1,009 ± 296 dynes-s-cmt",
p < 0.05) but no change in pulmonary capillary wedge
pressure (31 ± 6 to 25 ± 13 mm Hg, p = NS). Only
systemic vascular resistance and arteriovenous oxygen
difference were significantly decreased during exercise.
When restudied after 5 weeks of therapy, neither
cardiac output nor stroke volume showed a sustained
Although aided by the acceptance of vasodilator drugs into
clinical practice, the pharmacologic treatment of severe
chronic heart failure continues to be unsatisfactory in many
patients. A number of promising inotropic drugs are cur-
rently being tested (I). Of these, MOL 17,043 is a unique
pharmacologic compound with in vitro inotropic properties
and in vivo inotropic and vasodilator properties. Initial re-
ports (2,3) of open label short-term testing have suggested
that this drug has substantial beneficial hemodynamic effects.
Our broad experience with testing a variety of new drugs
for heart failure has shown that although short-term hemo-
dynamic effects are frequently useful for the initial assess-
ment of therapy, longer-term multifaceted testing is invar-
iably necessary to ultimately assess their utility. Because
no comprehensive profile of MOL 17,043 has been per-
formed in patients with chronic heart failure, we studied the
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increase at rest or during exercise, and effects on sys-
temic vascular resistance and arteriovenous oxygen dif-
ference were not sustained at exercise (p = NS). Peak
oxygen uptake during exercise was 8.1 ± 2.5 ml/kg per
minat baseline and was not significantly increased either
acutely (9.2 ± 2.4 ml/kg per min, p =NS)or chronically
(8.9 ± 2.2 ml/kg per min, p = NS). Problems of in-
creased ventricular arrhythmias and diarrhea were notecl
after therapy was begun. Clinical observation initially
included some imprevemeat in dyspnea and exercise ca-
pacity at 2 weeks of study, only to be followed by de-
terioration to baseline clinical status in most patients at
5 weeks. This study suggests that although short-term
clinical and hemodynamic observations may indicate
beneficial effects due to MOL 17,043 treatment, long-
term observations do not show sustained effect. In fact,
some serious side effects occur.
(J Am CoU CardioI1985;5:1422-7)
short- and long-term (5 week) effects on clinical and hemo-
dynamic responses at rest and during exercise.
Methods
Patients. We studied 10 patients with New York Heart
Association functional class III heart failure who at the time
of referral were considered refractory to their current med-
ical regimen. The patients (mean age 62 years, range 52 to
76) were electively admitted to the hospital at least 48 hours
before the study and their current medications, which always
included digitalis and diuretic drugs (mean furosemide dose
100 mg/day, range 40 to 240), were continued at customary
outpatient dosages. The heart failure was caused by ischemic
heart disease with prior myocardial infarction in six patients
and by idiopathic cardiomyopathy in four patients. Two
patients had previously undergone coronary bypass surgery;
no patient had ischemic chest pain at the time of admission.
Five patients had undergone previous outpatient trials of a
vasodilator drug, conducted by their referring physician,
without clinical improvement, but none had previously par-
ticipated in an experimental protocol. Our study was re-
0735-1 ~7/85/S3. 30
JACC Vol. 5. No.6
June 1985:1422-7
RUBIN ANDTABAK
MOL 17.043 IN HEART FAILURE
1423
viewed and approved by the Human Subjects Committee of
our institution, and patients gave written informed consent
before participating ill this study.
Variables studied. We inserted a right heart flotation
catheter and measured intracardiac pressures as well as ther-
modilution cardiac output. Blood pressure was measured
from an indwelling radial artery line, and heart rate and
rhythm were recorded on the electrocardiogram. Blood sam-
ples were obtained for pulmonary (mixed venous) and sys-
temic arterial measurements of blood gases and oxygen con-
tent, and analyzed on a blood gas analyzer and co-oximeter,
respectively. Expired respiratory gas was obtained for mea-
surements of ventilation, oxygen uptake and carbon dioxide
output by a pneumotachygraph and mass spectrometer. Ex-
ercise was performed on a weight-flywheel cycle ergometer.
The exercise protocol consisted of 3 minute stages beginning
at unloaded pedaling and incremented by 25 watts. Patients
exercised to their symptom-limited maximum. Technical
aspects of these measurements conformed to standard prac-
tice, and calculated variables conformed to standard for-
mulas as previously described by us in similar studies (4-6) .
Protocol. After an admission history, physical exami-
nation and laboratory tests , baseline rest and exercise hemo-
dynamics were studied in the morning after a liquid break-
fast. We measured supine, upright and exercise hemodynam-
ics as well as sitting and exercise gas exchange. On the basis
of preliminary dose ranging, safety and toxic studies, pa-
tients were titrated stepwise to 6 mg/kg of MDL 17,043
orally and then continued with this dose at 8 hour intervals
for three additional doses. Retesting of short-term effects
of MDL 17,043 was performed after the fourth dose using
the same protocol used in the baseline study. All 10 patients
were considered to have responded satisfactorily to these
initial studies and were then observed in a unit for moni-
tored, but ambulatory patients until clinically stable for dis-
charge. Weekly outpatient clinic visits occurred for the next
4 weeks, with clinical evaluation and laboratory work.
Patients were then readmitted to the hospitalfor the long-
term phase of the study and were maintained on their out-
patient drug regimen for 24 hours . Seven patients were
clinically stable and capable of restudy by the same protocol
used for baseline and short-term studies of rest and exercise
hemodynamics and gas exchange . Patients were then with-
drawn from MDL 17,043 treatment for 48 hours while all
other medications were maintained. Seven patients were
restarted on MDL 17,043 treatment and their clinical status
has been subsequently followed up on a monthly basis.
Statistical analysis. We performed a one-way analysis
of variance for repeated measures, and if significant, a mul-
tiple comparison test (7). Each variable was tested under
three conditions of study: supine , which included factors of
baseline, short-term, long-term and withdrawal data; up-
right, which included factors of baseline, short- and long-
term data and exercise, which included factors of baseline,
short- and long-term data. Statistical significance was set at
the probability level of less than 0 .05 .
Results
Short-term cardiopulmonary effects. Supine, upright
and exercise hemodynamics and gas exchange measure-
ments were performed at baseline and after four doses of
MDL 17,043 (Tables 1 and 2) . Baseline hemodynamic re-
sults showed typically abnormal values for patients with
heart failure: low cardiac output and stroke volume and high
pulmonary capillary wedge pressure at rest and during ex-
ercise. Repeat hemodynamic measurements obtained at su-
pine rest after short-term therapy showed a significant in-
crease in cardiac output of 56% (from 3.9 ± 0.7 to 6.1 ±
1.1 liters/min, p < 0.05), predominantly due to a 43%
increase in stroke volume (from 42 ± 12 to 60 ± 15 ml,
p < 0.05). Systemic vascular resistance was significantly
decreased by 35% (from 1,564 ± 326 to 1,009 ± 296
dynes-s-cm r", p < 0.05) . Upright hemodynamic measure-
ments at rest showed similar changes to those recorded for
the supine position. Although directionally similar, changes
in cardiac output and stroke volume during exercise were
smaller and not statistically significant. Arteriovenous ox-
ygen difference was significantly decreased at upright rest
and during exercise (p < 0.05) . Although there was a small
change in pulmonary capillary wedge pressure of - 19% at
rest and of +4% at exercise, the change was not consistent
and did not reach statistical significance. MDL 17,043 did
not significantly change heart rate, blood pressure, right
atrial pressure or pulmonary artery pressure either at rest or
during exercise (p = NS) .
Baseline peak oxygen uptake at exercise was 8.1 ± 2.5
ml/kg per min, and peak work load was 43 ± 12 watts
(Fig. I) . After short-term therapy, neither peak oxygen up-
take nor work load was changed (p = NS). Baseline gas
exchange data showed typical findings at rest and during
exercise, with nonnoxia in the blood gases and increased
ventilation as well as increased dead space in the gas ex-
change data . After short-term therapy, there were no sta-
tistically significant changes in these variables.
Clinical effects. Patients remained in the hospital for
the first week after the start of therapy . The following clin-
ical events were judged to be important and required cor-
rective action . Increased ventricular ectopic activity, in-
cluding short runs of ventricular tachycardia, was observed
in five patients. In these patients, MDL 17,043 dosage was
reduced from 6 to 4 mg/kg three times daily, and in three
of these patients a type I antiarrhythmic drug was started.
All 10 patients had an increase in the number and liquid
content of bowel movements. This usually reached a peak
shortly after the start of MDL 17,043 therapy and had de-
creased by the time of hospital discharge.
At the first week of outpatient follow-up, 6 of the 10
Table 1. Supine Hemodynamic Response at Rest in 10 Patients
Pulmonary Capillary
Cardiac Output Stroke Volume Wedge Pressure Vascular Resistance
Age
(liters/min) (ml) (mm Hg) (dynes -s-cm- 5)
Case (yr) Ox B A C W B A C W B A C W B A C W
I 52 CMP 4,9 7.5 7.2 6.8 63 89 100 III 38 48 20 13 1,078 789 967 894
2 64 CHO 4.5 5.9 3.2 * 39 55 29 * 28 26 34 * 1,884 1,220 1,775
3 57 CHD 3.6 6 .5 4 .1 3.9 43 72 46 42 24 20 28 28 1,733 960 1,483 1,703
4 60 CHD 2.9 4 04 4.0 3.3 24 36 40 31 32 36 28 15 2,04 1 1,473 1,900 2,158
5 57 CHD 4.3 6 .0 5.6 4.8 50 59 63 64 34 12 12 17 1,433 853 1,057 1,250
6 76 CMP 3.5 4 .7 4.4 4 .2 49 52 58 51 21 8 4" 9 1,714 1,328 1,564 1,505
7 65 CHD 4 04 6 .8 3.6 3.6 39 57 32 34 35 18 32 28 1,218 647· 1,156 1,111
8 72 CHD 5.0 6 .2 r- *~ 59 64 r- * --, 18 10 r-*~ 1,104 877 r- *"--.
9 63 CMP 4.2 5.3 r- *~ 48 52 r- *--' 35 34 r-*--, t ,252 996 r-*--.
10 50 CMP 3.2 6.6 3.8 3.5 30 60 35 40 33 28 33 32 1,450 800 1,263 1,097 "
Mean 3.9 6:1 4.5 4.2 42 60 50 50 31 25 24 22 1,564 1,009t 1,396 1,434
±SD ± 0 .7 ± I.l t ± 1.3 ± 1.2 ± 12 ± 15t ± 23 ± 27 ± 6 ± 13 ± I I ±IO ±326 ±296 ±340 ± 422
· Readmitted in unstable cond ition and excluded from analysis . t p < 0 .05 compared with baseline values. A = acute effects; B :: baseline values; C = chronic
effects; CHD = coronary heart disease; CMP =.:ardiomyopathy; Dx = cardiac diagnosis; W = withdrawal.
Table 2. Summary of M ean Hemodynamic Response s at Re st and Ex erci se
Supine
A C W
103 ± 14 94 ± 15 90 ±. 17
84 ± 14 87 ± 10 82 ± II
6.1 ± 1.1* 4.5 ± 1.3 4.2 ± 1.2
60 ± 15* 50 ± 23 50± 27
HR (min-I)
MAP (mm Hg)
CO (liters/min )
SV (ml)
av-~ (rnl/d l)
MPA (mm Hg)
PeW (mm Hg)
MRA (mm Hg)
SVR (dynes-s-cm - 5)
B
97 ± 19
90 ± 13
3.9 ± 0.7
42 ± 12
41 ± 7
31 ± 6
15 ± 8
1,564 ± 326
3J ± 12
25 ± 13
10 ± 7
1.009 ± 296*
34 ± 13
24 ± II
12 ± 7
1,396 ± 340*
31 ± II
22 ± 10
II ± 8
1,434 ± 422
B
102 ± 14
9 1 ± 12
4.1 ± 0.8
40 ± 10
7 04 ± 1.0
34 ± II
21 ± 9
4 ± 6
1,720 ± 319
Upright
A
108 ± 12
83 ± 14
5.5 ± 1.0*
52 ± 11*
6 .2 ± 104*
27 ± 9
18 ± 8
4 ± 5
1, 191 ± 323*
C
102 ± 12
88 ± 13
4 .0 ± 1.1
41 ± 18
7 .5 ± 1.7
29 ± 14
19 ± 13
5 ± 6
1,762 ± 608
B
117 ± II
9 1 ± to
6.5 ± 104
56 ± 14
13.2 ± 1.7
43 ± · 9
27 ±.8
12 ± 8
1,040 ± 286
Peak Exercise
A
124 ± 113
93 ± II
8.2 ± 1.2
68 ± 16
10.3 ± 2. 1*
42 ± 12
28 ± 13
12 ± 8
820 ± 228*
C
124 ± 9
100 ± 2 1
7.6 ± 3. 1
63 ± 32
I I.7 ± 2.7
40 ± 17
26 ± 14
12 ± 7
1,005 ± 341
All data are given as mean ± SO. *p < (},05 (study condition compared with baseline value) . av-Os = arterio venous oxygen difference; CO = cardiac output; HR
heart rate; MAP = mean arteri al pressure ; MPA = mean pulmonary artery pressure; MRA = mean right atrial pressure ; PCW = pulmonary capill ary wedge pressure;
SV = stroke volume ; SVR = systemic vascular resistance; other abbreviation s as in Table I .
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Figure1. Peak oxygen uptake and work load during exercise are
shown at baseline (B), short-term study (after four doses of MOL
17,043) (A) and long-term study (C) . Neither oxygen uptake nor
work load was changed during short- or long-term therapy (p =
NS).
Two of the latterpatients requiredshort-term hospitalization
for pulmonary congestion. They continued on the study
protocol after discharge. In one patient, there had been a
precipitous decrease in body weight and the development
of orthostatic hypotension; this patient required brief hos-
pitalization anda reduction indiuretic drugsandMDL 17,043.
History and physical examination suggested fluid retention
in the other six patients at this time and diuretic drugs were
increased. Laboratory values in the group at this time were
unchanged except for evidence of mild hyperosinophilia in
the peripheral blood count. By the fifth week of therapy
(fourth outpatient week), three patients were considered
clinically unstable and were admitted to the hospital, two
for uncontrolled heart failure and one for the development
of new atrial fibrillation. The final clinical assessment by
one of the investigators (S.A.R.) at this time was that two
patients had improved to functional class II, six patients
remained in class III and two patients' condition had de-
teriorated to class IV (Fig. 2).
Long-term hemodynamic effects. After 5 weeks of
therapy, the patients were readmitted to the hospital. Seven
of the original 10 patients were clinically stable. After 24
hours of bed rest and medication, they were restudied at
rest, during exercise and again at rest after withdrawal of
MDL 17,043 (Tables I and 2, Fig. I). Supine and upright
rest hemodynamics and arteriovenous oxygendifferencehad
returned toward baseline values. Cardiac output and stroke
volume were especially deteriorated compared with short-
termdrug administration, and not statisticallydifferentfrom
baselinevalues (p == NS). Only systemicvascularresistance
showed a sustained decrease (p < 0.05). Although pul-
monary capillary wedge pressure and other intracardiac
pressures were slightly lower than baseline values, this did
not reach statistical significance (p == NS). Blood pressure
and heart rate were unchanged . When MDL 17,043 treat-
ment was stoppedfor 48 hours and other medications main-
tained, there was no significant deterioration in the rest
hemodynamics of the group. However, two patients did
show a substantial reductionin cardiac output that improved
when the drug was restarted.
There were no significant cardiopulmonary effects de-
monstrable in the seven patients who completed this phase
of the testing (Fig. I). Chronically, peak oxygen uptakeand
work load were slightly, but not significantly, increased
(p == NS).
Long-term follow-up. MDL 17,043 was discontinued
in three patients immediately after the 5 week study period,
in two because of worsening heart failure without hemo-
dynamic benefit and in one because of sustained hemody-
namic improvement despite withdrawal of all medications .
This latter patient has improved to functional class I status
over the past 18 months with no treatment and has had a
normal examination. We assume he had a reversible form
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patients reported clinical improvement, 3 reported no change
and the condition of I had deteriorated. Evaluation by one
of us (S.A.R.) indicated that functional status, which was
originally class III, had improvedto class II in five patients
and was unchanged in five patients (Fig. 2). Our criteria
were decreased dyspnea and increased exercise capacity in
these five patients. Physical findings and laboratory values
were unchanged from baseline values in the group as a
whole. By the third week of outpatient follow-up, only two
patientscontinuedto report clinical improvement, whilefive
reported no change and the condition of three deteriorated.
Figure 2. Physician evaluation of New York Heart Association
functional status. At baseline, all 10 patients were in class III.
After 2 weeks of treatment, functional class in five patients had
improved to class II, but by 5 weeks of treatment the functional
class of only two patients remained improved to class II, while
that of two patients deteriorated to class IV. Seven patients con-
tinued with treatment; the condition of none of these improved .
Five of the seven subsequently died, one underwent heart trans-
plantation and one changed to treatment with captopril.
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of heart failure , probably alcohol -related . Of the seven pa-
tients who continued with treatment, two died suddenly 2.5
and 7.5 months into treatment, respectively. Three addi-
tional patients deteriorated clinically and died of worsening
heart failure at 2.5, 5 and 7.5 months into treatment, re-
spectively. The condition of one younger patient slowly
deteriorated but treatment was continued until a heart trans-
plant was performed 4.5 months into treatment. Only one
patient continued taking MDL 17,043 for 9 months until
his condition began to deteriorate and the drug was replaced
by captopri!. No patient remains on therapy .
Discussion
We studied the short- and long-term rest and exercise
cardiopulmonary and clinical responses to MDL 17,043 in
10 patients with chronic heart failure . We found that there
was increased cardiac output and stroke volume after 24
hours of therapy , with little change in filling pressures. Early
inpatient clinical evaluation suggested increased ventricular
arrhythmias and diarrhea. Although most of the patients had
some clinical improvement after 2 weeks of treatment, at 5
weeks only two patients had evidence of sustained clinical
improvement. Recurrent symptoms of shortness of breath
were especially prominent during long-term follow-up and
most of the patients required increased diuretic drugs. When
restudied at 5 weeks of therapy, the beneficial hemodynamic
effects had regressed to baseline values in most patients .
Cardiopulmonary evaluation showed no objective improve-
ment in exercise capacity. Withdrawal of MDL 17,043 at
that time suggested that the failure of sustained hemody-
namic effects (which occurred in most patients) was due to
lack of drug efficacy rather than to deterioration of pump
function. Subsequent long-term follow-up did not show clin-
ical improvement in those patients who continued with
therapy .
Review of reported MDL 17,043 effects. Several re-
cent reports have defined the short-term hemodynamic ef-
fects of MDL 17,043 at rest. Uretsky et a!' (2) first reported
the hemodynamic response of patients with heart failure to
intravenous MDL 17,043, and observed increases in cardiac
output and decreases in cardiac filling pressures for up to 6
hours after a single dose. Other investigators (3,8-tO) con-
firmed these acute hemodynamic findings and reported other
effects of this unique compound . Crawford et a!. (3) con-
firmed that MDL 17,043 has inotropi c effects (increased
dP/dt) in patients with heart failure, while Laskey et a!. (8)
showed that a related compound has similar effects. Vi-
guerat et al. (9) suggested that increased coronary flow and
oxygen uptake occurred without deterioration of myocardial
metabolic balance. Martin et al. (10) found similar effects ,
but also suggested that coronary shunting occurred that could
cause deterioration of myocardial metabolic balance. Craw-
ford et a!. (3) confirmed the acute hemodynamic effects of
MDL 17,043 and found no adverse findings in the bio-
chemical profile of patients to acute dosaging. Amin et a!.
(11,12) recently extended these acute findings in hemody-
namic studies comparing MDL 17,043 with nitroprusside
(11) and dobutamine (12). These carefully performed stud-
ies, using drugs that are considered archetypal vasodilator
and inotropic agents, suggested that MDL 17,043 has both
properties .
Differences found in our study. Our results differed
from those previously reported in the following respects.
Our short-term hemodynamic data were collected after 24
hours, which represented four doses of oral MDL 17,043
rather than after a single intravenous dose. Our findings
differed from other studies in that we could not demonstrate
a large reduction in pulmonary capillary wedge pressure ,
although a small decrease in wedge pressure was present in
some patients. This difference may be due to a diminution
of effect after a few doses of the drug , or to a difference
between the intravenous form of MDL 17,043 , which most
investigators have reported on, and the oral form that we
used. Similar to other investigators, we did find an imme-
diate increase in cardiac output and stroke volume or a
decrease in systemic vascular resistance. We did not in-
vestigate or distinguish between inotropic and vasodilator
effects of MDL 17,043.
We also developed data on the long-term hemodynamic
and cardiopulmonary response of the patients . These data
showed a decline in the initial beneficial hemodynamic ef-
fects of MDL 17,043 after 5 weeks of treatment. During
rehospitalization after 5 weeks of drug therapy, we withdrew
MDL 17,043 and restudied the hemodynamics. Cardiac pump
function did not change. Therefore, the loss of beneficial
effects that occurred in many patients was not due to de-
terioration of underlying pump function, which certainly
can occur in patients with heart failure, but rather to drug
tachyphylaxis. Some preliminary studies were performed to
address this issue. In three patients , some increase in cardiac
output was seen when higher oral doses were used while
two patients were unresponsive to any oral or intravenous
dosage . Diminished effectiveness could be due to a phar-
macologic mechanism, such as loss of phosphodieterase
inhibition. Other investigators (9, to, 13) have suggested ad-
verse myocardial effects, such as deterioration of myo-
cardial metabolism.
Exercise effects. We could not demonstrate any im-
provement in exercise capacity or peak oxygen uptake in
patients during the long-term part of the study. We note that
factors apart from central hemodynamics (physical condi-
tioning, behavioral aspects of disease, local muscle metab-
olism, concomitant diseases) may influence and change
exercise capacity (4). However, if it is assumed that hemo-
dynamic deterioration was the cause of the reduction
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in exercise capacity in patients with heart failure, then it is
reasonable to infer that a hemodynamic improvement is a
necessary effect (of treatment) to improve exercise capacity .
We fundamentally subscribe to this premise . Our hemo-
dynamic and exercise capacity data in response to long-term
MOL 17,043 therapy are congruent-there were only min-
imal changes in hemodynamic results and no improvement
in capacity. Some patients may show sustained clinical im-
provement. Kereiakas et al. (13) reported that at 5 .6 months'
mean follow-up , 12 of 37 patients were still taking MOL
17,043 and showed an improvement in functional class,
while Shah et al. (14) reported that at 2 months' follow-up,
6 of 13 patients had improvement, and at 5 months only 1
patient was still alive and in improved condition. However,
late follow-up in these studies did not include hemody-
namics or objective measurement of exercise capacity.
Side effects. Our protocol was also meant to define the
long-term clinical characteristics of MOL 17,043 in an open
label study . An increase in the number and liquid content
of bowel movements was observed in all patients early dur-
ing therapy, but the diarrhea had considerably lessened by
the end of the study. We do not know whether this im-
provement represented bowel motility tachyphylaxis to MOL
17,043; we took no extra measures to treat this symptom.
We observed troublesome ventriculararrhythmiasafter starting
MOL 17,043 treatment, which prompted us to reduce drug
dosage in these patients and to initiate type I antiarrhythmic
drug therapy . An early clinical improvement occurred in
some of the patients by 2 weeks, but no overall impression
of improvement was present at 5 weeks. Longer follow-up
of a subgroup of the original group patients has not shown
substantial clinical benefit. No important abnormal findings
of weekly laboratory tests were attributable to MDL 17,043,
although an increased eosinophil count was observed spo-
radically in many of the patients. We do not know the
meaning of this finding. During the long-term follow-up
period, two patients died of sudden death . However, our
substantial experience, as well as that of other investigators,
shows that sudden death occurs frequently in long-term open
label studies of patients with severe heart failure and, there-
fore, we are unable to assess the significance of this finding.
Implications. Early studies of the beneficial effects of
drug treatment in patients with chronic heart failure have
frequently been tempered by subsequent reports of clinical
utility. Drug investigations continue because of the mag-
nitude of the problem of heart failure and because no agent
has yet been found that results in substantial improvement
in the majority of severely ill patients. When beneficial
effects are shown in an uncontrolled study, it usually pro-
vides impetus for more substantial and controlled studies .
Essentially negative data , such as those reported here and
in other recent reports (13,14) , suggest caution before sub-
mitting a large number of patients and resources to additional
studies.
Robert Spangenburg, MD of Merrell-Dow arranged for drug supplies and
financial support of this study. We also greatly appreciate the dedication
of the coronary care unit nurses of Cedars-Sinai Medical Center in assisting
us. H. J. C. Swan , MD, PhD provided critical review and direction during
the preparation of this manuscript.
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